Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Matrixx issuing coupons for oral products

This article was originally published in The Tan Sheet

Executive Summary

In an effort to stay in business, Matrixx Initiatives expects to drive consumers to its Zicam oral cold remedies by using a "very large database" of customer information and distributing "high-value" coupons, according to Jim Marini, VP of sales. The Scottsdale, Ariz.-based firm looks to convert its customers to oral products following a June 16 voluntary recall of two homeopathic intranasal zinc-containing cold remedies after it received a warning letter from FDA that the products potentially cause anosmia, the loss of the sense of smell. FDA also told the firm to develop a plan to remove the affected Zicam products from the market (1"The Tan Sheet" June 29, 2009). At the National Association of Chain Drug Stores Marketplace trade show June 28 to July 1 in Boston, Marini said Matrixx is "informing retailers of our plans to grow our business" and of the firm's efforts to move consumers to alternative products. In an interview, Marini said Matrixx has received "overwhelming support" from its retailers

You may also be interested in...

Matrixx Must Transition Zicam Customers To Oral Products As Options Narrow

Salvaging the Zicam brand by shifting consumers to its oral delivery products will be crucial to the survival of Matrixx Initiatives, as the firm's strategic options narrow in the wake of a major recall

Separation Key To Posting Studies Linking Dietary Ingredients To Preventing Or Treating Disease

DSHEA’s Scientific Literature Exemption is attracting attention for offering online studies showing nutrients’ benefits on diseases including COVID-19, though the method isn’t free of risks, suggests CRN executive Megan Olsen.

Hanmi And LG Chem Highlight Vaccine Prowess, Novel R&D At JPM

Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts